Company / Current Liabilities
ArriVent BioPharma, Inc. Current Liabilities History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$17.3M
FY2024
5-year range
$11.6M / $17.3M
FY2023-FY2024
Trend
+48.6%
vs FY2023
Sector context
#194 of 213
Health Care
What the data says
Among 213 Health Care companies, ArriVent BioPharma, Inc. is in the top 9% for current liabilities.
Based on SEC 10-K filings.
$17M in FY2024.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 213This company $17.3M Sector average $1.6B
▼
-98.9% below sector average
Key checks
Key Insights
- In FY2024, current liabilities increased 48.6% year-over-year.
- Ranks #194 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $17.3M | +48.6% |
| FY2023 | $11.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026